# Study of ARO-CFB in Adult Healthy Volunteers

> **NCT06209177** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Arrowhead Pharmaceuticals** · enrollment: 49 (actual)

## Conditions studied

- IgA Nephropathy

## Interventions

- **DRUG:** ARO-CFB
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06209177
- **Lead sponsor:** Arrowhead Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-04-05
- **Primary completion:** 2025-03-31
- **Final completion:** 2026-03
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06209177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06209177, "Study of ARO-CFB in Adult Healthy Volunteers". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06209177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*